RUBY News and Press, Rubius Therapeutics Inc. From 09/13/22

Company to Focus on Advancing Next Generation Red Blood Cell-Based Cell Conjugation Platform Initiating Cost-Saving Measures Through Corporate Restructuring; Cash Runway Extended to End of 2023 Discontinuing Ongoing Phase 1 Clinical Trials of RTX-240 and RTX-224 in Advanced Solid ...

CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treat...

3 Penny Stocks to Add to Your Watchlist Right Now While finding the best penny stocks to buy can be tricky, there are plenty of ways to do just that. In 2022, the stock market has continued to move significantly in both directions, resulting in major gains for some and major losses for ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com It’s time for another overview of the biggest pre-market stock movers as we see what’s happening on Thursday! We’ve got earnings reports, stock offerings, clini...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com It’s time to start off the day with a breakdown of the biggest pre-market stock movers for Tuesday morning! Moving stocks this morning are clinical trial data, a business com...

Rubius Therapeutics press release ( NASDAQ: RUBY ): Q2 GAAP EPS of -$0.49 beats by $0.03 . cash, cash equivalents and investments were $140.7 million For further details see: Rubius Therapeutics GAAP EPS of -$0.49 beats by $0.03

New Preclinical Data Presented at the FOCIS 2022 Annual Meeting Demonstrating Prevention of Type 1 Diabetes in a Stringent Preclinical Model Initial Clinical Results Expected in 2H’22 from Phase 1 Arm of RTX-240 + Pembrolizumab in Advanced Solid Tumors and Expansion Cohorts in ...

CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatm...

HotSpot Therapeutics Appoints Jose Carmona to Board of Directors PR Newswire BOSTON , July 19, 2022 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule allosteric therapies for the treatme...

CAMBRIDGE, Mass., July 14, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatm...